National Center for Geriatrics and Gerontology Patent applications |
Patent application number | Title | Published |
20160029934 | LIQUID COLLECTING APPARATUS AND LIQUID COLLECTING METHOD - A suction drain device of a disclosed liquid collecting apparatus actively pushes and pulls blood. This achieves liquid collection at high speed even under decreased pressure depending on a physiological state of an animal. Moreover, the liquid collecting apparatus includes a First flow path and a second flow path having a given length. Accordingly, the flow path with a given length set in advance and thus a known volume allows collection of a given amount volume of blood without measuring a length and an amount of blood using a volume measuring device. Accordingly, no need of the measuring device allows reduction in size of the liquid collecting apparatus. Consequently, the liquid collecting apparatus can be installed adjacent to the animal to achieve reduction in dead volume. Moreover, blood is flown to a fourth flow path branched with a connecting terminal, and is also flown to the second flow path branched with a connecting terminal. The blood flown in the second flow path is collected at the highest priority. This obtains collection of fresh blood from a collecting source as a blood supply source. | 02-04-2016 |
20140249180 | TAU AGGREGATION INHIBITOR - A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy. | 09-04-2014 |
20140178992 | MEMBRANE-SEPARATION-TYPE CULTURE DEVICE, MEMBRANE-SEPARATION-TYPE CULTURE KIT, STEM CELL SEPARATION METHOD USING SAME, AND SEPARATION MEMBRANE - A membrane separation culture device includes an upper structure including a vessel in which at least a portion of the bottom thereof is formed with a separation membrane having pores that allow stem cells to permeate therethrough, and a lower structure including a vessel that retains a fluid in which the membrane of the upper structure is immersed. | 06-26-2014 |
20140099605 | UNEXTRACTED TOOTH ROOT CANAL FILLER AND DENTAL TISSUE REGENERATION METHOD FOR UNEXTRACTED TOOTH - Disclosed is a root canal filler for non-extracted tooth which causes no internal resorption or external resorption in a tooth with complete root formation, shows no odontoclast, and contributes to the regeneration of a dental tissue in which odontoblasts are smoothly aligned on the dentin wall. After pulpectomy or enlargement/cleaning of an infected root canal, a root canal filler for non-extracted tooth, which comprises tooth pulp stem cells and an extracellular matrix, is inserted into the apical side of the root canal of the non-extracted tooth. The tooth pulp stem cells may be, for example, dental pulp CXCR4-positive cells. It is preferred to attach, to the crown side of the root canal, migration factor(s) including at least one factor selected from among a cell migration factor, a cell proliferation factor, a neurotrophic factor and an angiogenic factor. | 04-10-2014 |
20130330303 | BRAIN TISSUE REGENERATION METHOD - A material for treatment of cerebral infarction ameliorates angiopathy at a cerebral infarction region and improves brain function. The material for treatment of cerebral infarction according to the present invention comprises a dental pulp stem cell including at least one of a CD105-positive cell, an SP cell, a CD24-positive cell, a CD271-positive cell, and a CD150-positive cell. The material for treatment of cerebral infarction according to the present invention may contain a secretory protein of the dental pulp stem cell. Transplanted dental pulp stem cells do not directly differentiate into neural progenitor cells or neural cells and indirectly participate in the promotion of differentiation to restore and cure a cerebral infarction region such that the region becomes normal. | 12-12-2013 |
20130149316 | Antibodies That Specifically Bind to Abeta Oligomers and Uses Thereof - The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease. | 06-13-2013 |
20120270177 | DENTAL ULTRASONIC DRUG DELIVERY SYSTEM AND DENTAL ULTRASONIC DRUG DELIVERY METHOD - A dental ultrasonic drug delivery system capable of accurately cleaning the inside of root canals and killing bacteria in dentin tubules is provided. The dental ultrasonic drug delivery system delivers a drug to a target using an ultrasonic delivery device | 10-25-2012 |
20120164604 | UNEXTRACTED TOOTH ROOT CANAL FILLER AND DENTAL TISSUE REGENERATION METHOD FOR UNEXTRACTED TOOTH - Disclosed is a root canal filler for non-extracted tooth which causes no internal resorption or external resorption in a tooth with complete root formation, shows no odontoclast, and contributes to the regeneration of a dental tissue in which odontoblasts are smoothly aligned on the dentin wall. After pulpectomy or enlargement/cleaning of an infected root canal, a root canal filler for non-extracted tooth, which comprises tooth pulp stem cells and an extracellular matrix, is inserted into the apical side of the root canal of the non-extracted tooth. The tooth pulp stem cells may be, for example, dental pulp CXCR4-positive cells. It is preferred to attach, to the crown side of the root canal, migration factor(s) including at least one factor selected from among a cell migration factor, a cell proliferation factor, a neurotrophic factor and an angiogenic factor. | 06-28-2012 |
20120141477 | Antibodies That Specifically Bind to ABeta Oligomers and Uses Thereof - The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease. | 06-07-2012 |
20110097319 | Antibody Capable of Binding Specifically to AB-Oligomer, and Use Thereof - The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease. | 04-28-2011 |
20100291071 | Antibody Specific Binding to A-Beta Oligomer and the Use - The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease. | 11-18-2010 |
20100260783 | Antibody Specific Binding to A Beta Oligomer and the Use - The present inventors successfully produced monoclonal antibodies that are specific to only soluble Aβ oligomers, but do not recognize soluble Aβ monomers, which are physiological molecules. It was demonstrated that the antibodies are useful as diagnostic/therapeutic monoclonal antibodies for Alzheimer's disease. | 10-14-2010 |
20080227694 | Novel Interaction Between Proteins, and Therapeutic Agent for Disuse Muscular Atrophy or Method Associated with Disuse Muscular Atrophy Taking Advantage of Novel Interaction - [Problem] Providing a novel interaction between proteins. | 09-18-2008 |